Omalizumab in allergic diseases, a recent review - PubMed (original) (raw)

Affiliations

• PMID: 22053590

Free article

Review

Omalizumab in allergic diseases, a recent review

Pakit Vichyanond. Asian Pac J Allergy Immunol. 2011 Sep.

Free article

Abstract

Omalizumab is a biological engineered molecule, targeting the Cepsilon3 domain of the IgE molecule. It binds with free IgE and prevents free IgE from attaching to high-affinity IgE receptor (FcepsilonRI) on effector cells such as mast cells, basophils and also on dendritic cells. The result is a blocking of mediator release from these cells and the inhibition of antigen presentation by dendritic cells. In addition, omalizumab downregulates FcepsilonRI expression on these effector cells. Omalizumab prevents early and late phase allergic reactions of skin and lungs. Omalizumab has been investigated extensively in moderate-to-severe asthma in adults and children. It effectively reduces rates of asthma exacerbation, emergency visits for asthma and hospital admissions among these patients. Currently, omalizumab is primarily indicated for patients, age 6 years and over, with moderate to severe asthma (GINA step 4). Omalizumab was investigated in patients with seasonal allergic rhinitis (to ragweed, birch and grass pollens) and has been found to improve rhinitis symptoms and to reduce medication use among these patients. Administered together with allergen immunotherapy, omalizumab reduced incidence of side effects and rates of anaphylaxis from allergen immunotherapy. Omalizumab has been investigated in the treatment of food allergy, atopic dermatitis and urticaria. Despite benefits observed from these initial trials, it further deserves investigations to clarify optimal conditions for use in these conditions. Side effects from omalizumab were few, however, it requires careful considerations in administration of this agent. An observational period (up to 2 hours after the first three doses) and the availability of auto-injectable epinephrine are recommended. Pharmacoeconomics of omalizumab is briefly reviewed. Omalizumab represents a major breakthrough of translational medicine in allergy.

PubMed Disclaimer

Similar articles

• Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases.
  D'Amato G, Liccardi G, Noschese P, Salzillo A, D'Amato M, Cazzola M. D'Amato G, et al. Curr Drug Targets Inflamm Allergy. 2004 Sep;3(3):227-9. doi: 10.2174/1568010043343615. Curr Drug Targets Inflamm Allergy. 2004. PMID: 15379589 Review.
• Omalizumab beyond asthma.
  Sanchez J, Ramirez R, Diez S, Sus S, Echenique A, Olivares M, Cardona R. Sanchez J, et al. Allergol Immunopathol (Madr). 2012 Sep-Oct;40(5):306-15. doi: 10.1016/j.aller.2011.09.011. Epub 2012 Jan 20. Allergol Immunopathol (Madr). 2012. PMID: 22264640 Review.
• Anti-IgE--emerging opportunities for Omalizumab.
  Babu KS, Polosa R, Morjaria JB. Babu KS, et al. Expert Opin Biol Ther. 2013 May;13(5):765-77. doi: 10.1517/14712598.2013.782391. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23517576 Review.
• Omalizumab in asthma: an update on recent developments.
  Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, Holgate S. Humbert M, et al. J Allergy Clin Immunol Pract. 2014 Sep-Oct;2(5):525-36.e1. doi: 10.1016/j.jaip.2014.03.010. Epub 2014 Jun 11. J Allergy Clin Immunol Pract. 2014. PMID: 25213045 Review.
• Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
  [No authors listed] [No authors listed] BioDrugs. 2002;16(5):380-6. doi: 10.2165/00063030-200216050-00009. BioDrugs. 2002. PMID: 12408744

Cited by

• The Efficacy and Safety of a Fixed Combination of Chinese Herbal Medicine in Chronic Urticaria: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
  Yang SH, Lin YH, Lin JR, Chen HY, Hu S, Yang YH, Yang YH, Yang YS, Fang YF. Yang SH, et al. Front Pharmacol. 2018 Dec 18;9:1474. doi: 10.3389/fphar.2018.01474. eCollection 2018. Front Pharmacol. 2018. PMID: 30618764 Free PMC article.
• Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.
  Lieberoth S, Thomsen SF. Lieberoth S, et al. Case Rep Med. 2015;2015:903541. doi: 10.1155/2015/903541. Epub 2015 Jan 28. Case Rep Med. 2015. PMID: 25694784 Free PMC article.
• Effects of omalizumab treatment in patients with refractory chronic urticaria.
  Nam YH, Kim JH, Jin HJ, Hwang EK, Shin YS, Ye YM, Park HS. Nam YH, et al. Allergy Asthma Immunol Res. 2012 Nov;4(6):357-61. doi: 10.4168/aair.2012.4.6.357. Epub 2012 Apr 20. Allergy Asthma Immunol Res. 2012. PMID: 23115733 Free PMC article.
• Adrenal insufficiency is a contraindication for omalizumab therapy in mast cell activation disease: risk for serum sickness.
  Molderings GJ, Dumoulin FL, Homann J, Sido B, Textor J, Mücke M, Qagish GJ, Barion R, Raithel M, Klingmüller D, Schäfer VS, Hertfelder HJ, Berdel D, Tridente G, Weinstock LB, Afrin LB. Molderings GJ, et al. Naunyn Schmiedebergs Arch Pharmacol. 2020 Sep;393(9):1573-1580. doi: 10.1007/s00210-020-01886-2. Epub 2020 May 6. Naunyn Schmiedebergs Arch Pharmacol. 2020. PMID: 32377770 Free PMC article. Review.
• CC-chemokine CCL15 expression and possible implications for the pathogenesis of IgE-related severe asthma.
  Shimizu Y, Dobashi K. Shimizu Y, et al. Mediators Inflamm. 2012;2012:475253. doi: 10.1155/2012/475253. Epub 2012 Oct 31. Mediators Inflamm. 2012. PMID: 23258953 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Allergy and Immunology Society of Thailand

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information